Mela's CFO finds the door; Smiths snags FDA clearance for pump;

@FierceMedDev: Wright ends an up-and-down year on a high note. More | Follow @FierceMedDev

@MarkHFierce: There's time to offer public comment on CMS's reduced payments for BRCA tests, and Myriad plans to speak up. Story | Follow @MarkHFierce

@MichaelGFierce: News from the holidays at FierceMedicalDevices: J&J nears the sale of its Ortho clinical Dx division, and more. Round-up | Follow @MichaelGFierce

@GalenMoore: The United States' global share of biomedical research spending fell from 51% in 2007 to 45% in 2012. Report | Follow @GalenMoore

> The CFO of troubled Mela Sciences ($MELA) resigned on Dec. 31. CEO Rose Crane is filling in while the New York company seeks a replacement. More

> Vital Signs, the GE Healthcare ($GE) unit soon to become part of CareFusion ($CFN), is recalling a disposable anesthesia device. News

> Smiths Medical won FDA clearance for a new infusion pump paired with software designed to regulate delivery. Item

Biotech News

@FierceBiotech: U.S. domination of global biomedical R&D slips as Asian budgets swell. News | Follow @FierceBiotech

@JohnCFierce: Is it human, animal or plant? At Bayer, they're mixing all three in new R&D recipe. Story | Follow @JohnCFierce

@DamianFierce: ICYMI: FDA spurns Sanofi's MS drug Lemtrada on fatally flawed PhIII design. More | Follow @DamianFierce

@EmilyMFierce: A New York Times reporter gets her DNA analyzed by three companies with varying results. Piece from NYT | Follow @EmilyMFierce

> Revance, Dicerna ring out an IPO boom year with $155M in pitches. More

> FDA lifts a partial hold on Cell Therapeutics' leukemia drug. Story

> NVCA starts 2014 with a hopeful wrap-up on the biotech IPO party. News

Pharma News

@FiercePharma: Top FiercePharma news this AM: Merck to cut 150 jobs from Saphris sales team. Sold drug to Forest last month. Story | Follow @FiercePharma

@EricPFierce: FDA says nada to Lemtrada; will Sanofi be willing to invest in additional trials? Story | Follow @EricPFierce

@CarlyHFierce: ICYMI Tuesday: China suspends imports of Pfizer's antifungal Diflucan on a paperwork problem. Story | Follow @CarlyHFierce

> China plans to blacklist drugmakers for bribery; violators will be suspended. More

> Cue more drama in Teva's boardroom as its CEO announcement nears. Article

> Mulling a Zilmax relaunch, Merck faces reports of hoofless cattle and skeptical customers. Report

Pharma Manufacturing News

> J&J moves forward with its plan to make Doxil in part of the closed Ben Venue plant. More

> Hospira's India plant disappoints the FDA again. Story

> China takes aim at poor-quality drug production. More

> Baxter initiates a 4-country recall after particulate is found in solutions. News

> Transfer of GSK plant to Aspen Pharmacare will wait until midyear. Report

> $100M fund outlined for victims of NECC manufacturing problems. Item

Vaccines News

> CDC warns H1N1 virus is causing severe flu in young adults. More

> Genocea files IPO papers in a bid to raise $75M for vaccine development. Story

> Falsified AIDS vaccine data lands researcher an NIH funding ban. Article

> New Chinese quality standards raise the risk of a hep B vaccine shortage. News

> Argos to test investor appetite for cancer vaccines with a $60M IPO. Report

> FIT Biotech is set to start a Phase III HIV vaccine trial. Item

Suggested Articles

Sherlock Biosciences teamed up with Cepheid to help develop its CRISPR-based molecular diagnostic tech in oncology, infections and the coronavirus.

The spine surgery company ATEC has moved to acquire Paris-based EOS imaging, makers of FDA-cleared scanners and 3D orthopedic planning software.

Digital molecule designer Insilico Medicine has launched a new preclinical research program focused on treatments for brain cancer.